/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Lantern Pharma Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.53 0.0202(2.02%) LTRN at 04 Dec 2025 04:37 PM Biotechnology
Lowest Today 3.35
Highest Today 3.565
Today’s Open 3.5
Prev. Close 3.47
52 Week High 6.12
52 Week Low 2.55
Day’s Range: Low 3.35 High 3.565
52-Week Range: Low 2.55 High 6.12
1 day return -
1 Week return -1.65
1 month return -
3 month return -14.62
6 month return +6.58
1 year return -4.04
3 year return -28.8
5 year return -77.09
10 year return -

Institutional Holdings

BIOS CAPITAL MANAGEMENT, LP 9.96

Vanguard Group Inc 3.37

Vanguard Total Stock Mkt Idx Inv 2.32

CM Management, LLC 1.85

Geode Capital Management, LLC 0.85

Renaissance Technologies Corp 0.84

Vanguard Institutional Extnd Mkt Idx Tr 0.63

Goss Wealth Management LLC 0.52

Voss Capital LLC 0.46

Fidelity Extended Market Index 0.40

BlackRock Inc 0.39

Dimensional Fund Advisors, Inc. 0.38

Westside Investment Management, Inc. 0.33

Horizon Kinetics Medical ETF 0.27

Horizon Asset Management Inc/ny 0.26

Bank of New York Mellon Corp 0.25

Davenport & Company LLC 0.24

UBS Group AG 0.23

State Street Corp 0.22

DFA US Targeted Value I 0.20

Commonwealth Equity Services Inc 0.17

iShares Micro-Cap ETF 0.17

Northern Trust Corp 0.14

Fidelity Total Market Index 0.14

Extended Equity Market Fund K 0.14

XTX Topco Ltd 0.12

Fidelity Series Total Market Index 0.11

Spartan Extended Market Index Pool F 0.10

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

Fidelity Nasdaq Composite Index 0.06

NT Ext Equity Mkt Idx Fd - NL 0.06

Vanguard Instl Ttl Stck Mkt Idx Tr 0.06

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

Wells Fargo & Co 0.05

Spartan Total Market Index Pool G 0.04

Dimensional US Targeted Value ETF 0.03

DFA US Vector Equity Class F 0.03

Group One Trading, LP 0.03

DFA US Core Equity 2 I 0.03

Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 38.81 M

PB Ratio 4.2233

PE Ratio 0.0

Enterprise Value 28.22 M

Total Assets 25.57 M

Volume 279877

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-15156718 -15.2M, FY22:-14087139 -14.1M, FY21:-12295100 -12.3M, FY20:-5908190 -5.9M, FY19:-2428185 -2.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:100654 0.1M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-4102 -0.0M, Q2/2025:-4501 -0.0M, Q1/2025:-4574 -0.0M, Q3/2024:null 0.0M, Q2/2024:-46266 -0.0M

Quarterly Net worth Q3/2025:-4177423 -4.2M, Q2/2025:-4331015 -4.3M, Q1/2025:-4536783 -4.5M, Q3/2024:-4505697 -4.5M, Q2/2024:-4959506 -5.0M

Fund house & investment objective

Company Information Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Organisation Biotechnology

Employees 24

Industry Biotechnology

CEO Mr. Panna Sharma

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow